Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular
Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet)
Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels
in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to
maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual
acuity in wet AMD, it is important to accurately measure anatomic response to treatments
thereby enhancing the ability to understand patterns of response and predict the necessity
for continued therapy.